As part of its drive to accelerate innovation and digital healthcare solutions, global pharmaceutical giant AstraZeneca is investing ₹176 crore to expand its Global Innovation and Technology Centre (GITC) in Chennai, strengthening its teams in AI, data science, and advanced analytics.
This marks AstraZeneca’s third major investment in India in the past two years.
Managing Director of AstraZeneca India Pvt Ltd, Siva Padmanabhan, said, “This new investment reflects our ongoing mission to improve patient lives by embedding cutting-edge technologies into every aspect of our work. Chennai continues to evolve as a vital innovation hub, and our continued growth here demonstrates the state’s boundless potential”.
The expansion is expected to accelerate the development of new medicines and support digital healthcare solutions.
Chief Minister, M.K. Stalin, Tamil Nadu, praised the move, stating: “This additional investment in Chennai is a testament to the state’s reputation as a centre of excellence for global innovation.”
AstraZeneca already maintains a strong presence in India, focusing on technology, global business services, and research and development, employing more than 5,000 people in the country, including staff at the GITC.
About the Author
